Gerardo Botti

发表

Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study.

G. Viale, F. Montemurro, M. Donadio, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.